What Is rEEG®?
One in four of us will suffer a diagnosable mental illness in a given year. And when that happens, our doctors will face a vast array of prescription drugs, with little more than symptoms to go on. No surprise, then, that treatment failures in disorders like depression range from 40-60%.
We were the first company to create biomarkers which predict the effectiveness of drugs based on the unique electrical signature of each person's brain. Some call it "personalized medicine".
We call it Referenced-EEG®, a patented process which has helped thousands. In a series of clinical trials on patients who suffered for years without responding to treatment, physicians guided over 75% of them to medications that worked. Often the right medication was a novel combination of two medications. And sometimes, the right answer was no medication at all.
We were the first company to create biomarkers which predict the effectiveness of drugs based on the unique electrical signature of each person's brain. Some call it "personalized medicine".
We call it Referenced-EEG®, a patented process which has helped thousands. In a series of clinical trials on patients who suffered for years without responding to treatment, physicians guided over 75% of them to medications that worked. Often the right medication was a novel combination of two medications. And sometimes, the right answer was no medication at all.
More
What does a report look like?
rEEG® findings are presented in a brief,
2-page report which characterizes any
underlying abnormality in the brain, identifies resistance or sensitivity to major drug classes
and individual medications.
2-page report which characterizes any
underlying abnormality in the brain, identifies resistance or sensitivity to major drug classes
and individual medications.
View Sample Report
Find a Licensed rEEG® Professional
What's New
- New Referenced-EEG® (rEEG®) Research Posters
- CORPORATE UPDATE CONFERENCE CALL: Audio replay
- United Biosource Corporation - Comparing Levels of Evidence for Treatment of Treatment-Resistant Depression with Referenced-EEG to Current Practice
- Analysis Group - Economic Impact of Referenced-EEG in Treatment Resistant Mental Health Conditions: Payer Perspective
- CLINICAL TRIAL NOW RECRUITING: Not Responding Well to Antidepressants?